JP2024516575A5 - - Google Patents
Info
- Publication number
- JP2024516575A5 JP2024516575A5 JP2023562827A JP2023562827A JP2024516575A5 JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5 JP 2023562827 A JP2023562827 A JP 2023562827A JP 2023562827 A JP2023562827 A JP 2023562827A JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- tlr7
- immunomodulatory composition
- motif
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176128P | 2021-04-16 | 2021-04-16 | |
| US63/176,128 | 2021-04-16 | ||
| PCT/US2022/025128 WO2022221736A2 (en) | 2021-04-16 | 2022-04-15 | Optimized tlr7 ligands and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516575A JP2024516575A (ja) | 2024-04-16 |
| JP2024516575A5 true JP2024516575A5 (enExample) | 2025-04-18 |
Family
ID=81940670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562827A Pending JP2024516575A (ja) | 2021-04-16 | 2022-04-15 | 最適化されたｔｌｒ７リガンド及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240042019A1 (enExample) |
| EP (1) | EP4323525A2 (enExample) |
| JP (1) | JP2024516575A (enExample) |
| CN (1) | CN117203340A (enExample) |
| WO (1) | WO2022221736A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4601656A1 (en) * | 2022-10-12 | 2025-08-20 | Pharmorage Pty Limited | Modified oligonucleotides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2311848T3 (da) | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| US8003619B2 (en) * | 2004-12-09 | 2011-08-23 | Alnylam Pharmaceuticals, Inc. | Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide |
| EP1924284A1 (en) * | 2005-09-14 | 2008-05-28 | Hartmann, Gunther | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
| EP2357231A2 (en) * | 2007-07-09 | 2011-08-17 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| CN102361981A (zh) * | 2009-02-10 | 2012-02-22 | 艾德拉药物股份有限公司 | Tlr7的合成rna基激动剂 |
| EP3263707A1 (en) | 2009-03-17 | 2018-01-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Tlr8 ligand and uses thereof |
| US9187746B2 (en) * | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| CA3043033A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
| US20220177423A1 (en) | 2019-04-18 | 2022-06-09 | Translate Bio, Inc. | Cystine cationic lipids |
| EP3959314A4 (en) | 2019-04-26 | 2023-02-08 | Genevant Sciences Gmbh | LIPIDNANOPARTICLES |
-
2022
- 2022-04-15 CN CN202280028901.4A patent/CN117203340A/zh active Pending
- 2022-04-15 EP EP22726552.7A patent/EP4323525A2/en active Pending
- 2022-04-15 WO PCT/US2022/025128 patent/WO2022221736A2/en not_active Ceased
- 2022-04-15 JP JP2023562827A patent/JP2024516575A/ja active Pending
-
2023
- 2023-10-12 US US18/485,987 patent/US20240042019A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7115579B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| TWI786401B (zh) | 用於抑制ｂ型肝炎病毒基因表現之組合物及方法 | |
| JP2025106391A (ja) | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 | |
| US7176296B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| JP2021526804A5 (enExample) | ||
| KR101835401B1 (ko) | 키랄 핵산 어쥬번트 | |
| CN101460178B (zh) | 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物 | |
| JP2023179428A (ja) | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 | |
| US7709449B2 (en) | Nucleic acid-based compounds and methods of use thereof | |
| US7105495B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
| AU2017203714A1 (en) | Immunostimulatory oligonucleotides | |
| JP2019527694A (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| WO1997029757A1 (en) | Rnase l activators and antisense oligonucleotides effective to treat rsv infections | |
| JPH08502040A (ja) | ハイブリッド オリゴヌクレオチド ホスホロチオエート | |
| JP2008523094A5 (enExample) | ||
| JPH09510714A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| JPH10510433A (ja) | 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド | |
| CN114206463A (zh) | 脂质化合物和脂质纳米颗粒组合物 | |
| CN115176009A (zh) | 用于靶向pd-l1的方法和组合物 | |
| EP2943251B1 (en) | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response | |
| JP2014532400A (ja) | 免疫賦活用の二本鎖ｒｎａ | |
| CN104011209A (zh) | 病毒基因表达的抑制 | |
| US20240327847A1 (en) | Compositions and methods for rna affinity | |
| JP2024539093A (ja) | ２’－デオキシ－２’－ｆ－２’－ｃ－メチルヌクレオチドを有するオリゴヌクレオチド | |
| CN106467915B (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 |